Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ampio Pharmaceuticals (NY: AMPE )

0.8400 USD UNCHANGED
Streaming Delayed Price Updated: 5:59 PM EST, Nov 24, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 873,272
Open 0.8300
Bid (Size) 0.8451 (1)
Ask (Size) 0.8569 (1)
Prev. Close 0.8400
Today's Range 0.8000 - 0.8600
52wk Range 0.3100 - 1.390
Shares Outstanding 86,320,968
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the... 
From PR Newswire
Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the... 
From PR Newswire

Performance

YTD
+43.05%
+43.05%
1 Month
+7.69%
+7.69%
3 Month
+15.86%
+15.86%
6 Month
+47.37%
+47.37%
1 Year
+98.77%
+98.77%

More News

Read More
Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results
From PR Newswire
Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th
From PR Newswire
Ampio Begins Phase 1 Clinical Trial of Inhaled Ampion For COVID-19 Patients With Respiratory Distress
From PR Newswire
Ampio Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event "COVID-19 Therapeutics in Development"
From PR Newswire
Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities
From PR Newswire
Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation
From PR Newswire
Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer
From PR Newswire
FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress
From PR Newswire
Ampion Phase I COVID-19 Patient Trial Results Featured on FOX News (Video)
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.